现代抗逆转录病毒治疗中断后病毒反弹时间
结果显示反弹中位时间22天,早期治疗者停药12周仍保持停药比例更高(9% vs 2%,P=.0496),所有参与者重启ART后均再抑制。
要点
- 现代ART中断后病毒反弹中位时间约22天,重启阈值为连续2次VL≥1000 copies/mL。
- 早期启动ART者中断后12周仍停药比例高于慢性期者(9% vs 2%,P=.0496)。
- 所有参与者重启ART后病毒载量均再抑制,急性逆转录病毒反弹综合征见于9%慢性治疗者。
核心结论
- 早期启动ART(无论新旧方案)与治疗中断后HIV反弹时间显著延迟相关,降低了HIV缓解的门槛。
研究设计与样本
- ACTG A5345前瞻性队列纳入慢性期或早期启动ART且抑制≥2年的HIV感染者,进行监测下治疗中断,并与6项历史ACTG治疗中断研究比较。
主要发现
- 急性逆转录病毒反弹综合征在慢性治疗者中诊断率为9%,早期治疗者中无。
- A5345与历史研究在病毒反弹时间上无差异;历史研究全部使用较老的蛋白酶抑制剂方案,A5345中97%使用整合酶抑制剂。
- 联合分析中,中断后第12周仍停药比例早期治疗者高于慢性治疗者(9% vs 2%,P=.0496)。
- A5345中1例慢性治疗者和1例早期治疗者停药超过24周,所有参与者重启ART后均再抑制。
关键数值与推荐
- 病毒反弹定义为连续2次病毒载量≥1000 copies/mL。
- 早期治疗者中断后12周仍停药比例为9%,慢性治疗者为2%(P=.0496)。
临床怎么用
- 监测下治疗中断时需以连续2次VL≥1000 copies/mL作为重启ART阈值。
- 早期启动ART者中断后病毒反弹可能延迟,但仍需严密监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Development of human immunodeficiency virus (HIV) remission strategies requires precise information on time to HIV rebound after treatment interruption, but there is uncertainty regarding whether modern antiretroviral therapy (ART) regimens and timing of ART initiation may affect this outcome. METHODS: AIDS Clinical Trials Group (ACTG) A5345 enrolled individuals who initiated ART during chronic or early HIV infection and on suppressive ART for ≥2 years. Participants underwent carefully monitored antiretroviral interruption. ART was restarted upon 2 successive viral loads ≥1000 copies/mL. We compared participants of A5345 with participants of 6 historic ACTG treatment interruption studies. RESULTS: Thirty-three chronic-treated and 12 early-treated participants interrupted ART with evaluable time to viral rebound. Median time to viral rebound ≥1000 HIV RNA copies/mL was 22 days. Acute retroviral rebound syndrome was diagnosed in 9% of the chronic-treated and none of the early-treated individuals. All participants of the historic studies were on older protease inhibitor-based regimens, whereas 97% of A5345 participants were on integrase inhibitor-based ART. There were no differences in the timing of viral rebound comparing A5345 versus historic studies. In a combined analysis, a higher percentage of early-treated participants remained off ART at posttreatment interruption week 12 (chronic vs early: 2% vs 9%, P = .0496). One chronic-treated and one early-treated A5345 participant remained off ART for >24 weeks. All participants resuppressed after ART reinitiation. CONCLUSIONS: Early ART initiation, using either older or newer ART regimens, was associated with a significant delay in the time to HIV rebound after ART interruption, lowering the barrier for HIV remission.
引用
- Li JZ, Aga E, Bosch RJ, et al. Time to Viral Rebound After Interruption of Modern Antiretroviral Therapies. Clin Infect Dis. 2022. PMID: 34117753. doi:10.1093/cid/ciab541
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。